Today's Trend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has been getting a mix of analyst updates and clinical-trial headlines, but the main stock-moving catalyst appears to be recent trial news. The stock has generally been pressured by a mixed Phase 3 readout for BMN 401 in ENPP1 deficiency, though that was partly offset by encouraging data from Voxzogo in hypochondroplasia.
- BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
- Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
- Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
- BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
- The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title
Overall, BMRN appears to be trading on the tug-of-war between a disappointing BMN 401 update and encouraging Voxzogo data, with analyst notes adding some support but not changing the core story.